IMNN Share Price Performance
US$9.20
-9.10 (-49.73%)
Price US$9.20
Share PriceUS$9.20
IMNN Community Narratives
There are no narratives available yet.
Recent IMNN News & Updates
No updates
Imunon, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
Aug 05, 2025
- Earnings per share (EPS)
- -8.39
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
Imunon, Inc. Competitors
About IMNN
- Founded
- 1982
- Employees
- 25
- CEO
- WebsiteView website
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines. The company’s lead clinical program is IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; and PlaCCine for the coding of viral antigens that can elicit a strong immunological response. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.
U.S. Market Performance
- 7 Days: -2.7%
- 3 Months: 11.4%
- 1 Year: 20.5%
- Year to Date: 5.9%
Over the last 7 days, the market has dropped 2.7%, driven by a decline of 2.4% in the Information Technology sector. As for the longer term, the market has actually risen by 20% in the last year. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading